DuPont De Nemours (DD) Proxy filing summary

Executive summary

• The annual meeting is scheduled for May 21, 2026, with voting on four key agenda items: election of 11 directors, advisory approval of executive compensation, ratification of PricewaterhouseCoopers LLP as auditor, and approval of a reverse stock split and reduction in authorized shares.

• The company completed significant portfolio changes, including the Electronics Separation, Aramids Divestiture, and realignment into Healthcare & Water Technologies and Diversified Industrials segments.

• 2025 financial highlights include $6.8B in net sales, $98M GAAP income from continuing operations, $1.63B operating EBITDA, and $1.68 adjusted EPS.

Voting matters and shareholder proposals

• Shareholders will vote on director elections, executive compensation (say-on-pay), auditor ratification, and a reverse stock split with authorized share reduction.

• The board recommends voting FOR all proposals.

• Proxy access is available for eligible shareholders to nominate directors.

Board of directors and corporate governance

• 11 director nominees, with 9 independent; annual elections by majority vote.

• Board leadership includes a non-executive Chairman and an independent Lead Director.

• Committees: Audit, Nomination and Governance, People and Compensation; all committee members are independent.

• Annual board and committee self-evaluations, director retirement policy at age 75, and robust stock ownership requirements.

• Board oversees risk management, succession planning, and engages regularly with shareholders.